Datametrex Confirms COVID-19 Test Kits Are Capable Of Detecting New Strain Of Virus

Datametrex AI Limited (TSXV: DM) this morning issued a quick update to the market. The company has indicated that it has received confirmation from its supplier for the 1copy™ COVID-19 qPCR Multi Kit, which is Health Canada approved, that it is capable of detecting the new strain of COVID-19.

Datametrex AI's Logo

The new coronavirus strain, which is thought to have originated within the United Kingdom wherein it is currently spreading rapidly, is a mutation of COVID-19 that is thought to be up to 70% more infectious. The strain has reportedly already entered Canada and the United States, along with numerous other global regions as reports continue to arise.

The manufacturer of Datametrex’s test kits officially confirmed via a report on December 25, 2020, that it is capable of detecting this new strain.

“This new mutated strain of COVID and its potential spread beyond the UK clearly demonstrates the importance of testing travelers. If testing was made mandatory before any travel was permitted, the globe would have a better chance of containing and preventing the spread of COVID-19.”

Marshall Gunter, CEO of Datametrex AI

Datametrex AI last traded at $0.14 on the TSX Venture.

Altamira Gold Corp. — sponsored Sponsored · Altamira Gold Corp.

FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Building the $500M-a-Year Gold Mine | Victor Cantore – Amex Gold Mining

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Datametrex: COVID-19 Testing Continues To Thrive Despite Vaccines – The Daily Dive

For the final episode of the trading week, we see the return of Datametrex AI...

Friday, June 4, 2021, 01:30:00 PM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

Sona Nanotech: Health Canada Evaluation Results Did Not Match Prior Analytical And Clinical Study Data

Sona Nanotech (CSE: SONA) this morning elaborated on its decision to withdraw its antigen test...

Monday, November 30, 2020, 09:16:04 AM

Datametrex To Sell Health Canada Approved COVID-19 Test Kits

Datametrex AI (TSXV: DM) announced this morning that it has obtained non-exclusive rights to a...

Monday, May 11, 2020, 10:56:16 AM

Datametrex AI To Launch AnalyticsGPT For Consumers

Datametrex AI (TSXV: DM) appears to be finally taking its name to heart and placing...

Tuesday, February 7, 2023, 08:34:04 AM